Michael Veliky
Optometrist · Iselin, NJNPI 1659359289
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,904 of the $6,483 with a category attached, or 75.6%. It is spread thinly across 22 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $49.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- AbbVie$1K
- Johnson & Johnson Surgical Vision, Inc.$769
- Alcon$658
- Sun Pharmaceutical Industries Inc.$451
- Sight Sciences, Inc.$420
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$1,50023%
- Food & beverage$4,90476%
- Education$401%
- Gifts$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $1,533 |
| AbbVie(2 entities) | 45 | $1,061 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $769 |
| Alcon | 7 | $658 |
| Sun Pharmaceutical Industries Inc. | 9 | $451 |
| Sight Sciences, Inc. | 6 | $420 |
| Topcon Healthcare, Inc. | 3 | $347 |
| Dompe US, Inc. | 9 | $206 |
| Bausch & Lomb Americas Inc. | 5 | $154 |
| Rxsight Inc | 1 | $132 |
| Eyevance Pharmaceuticals LLC | 1 | $126 |
| Aerie Pharmaceuticals, Inc. | 6 | $112 |
| LKC Technologies, Inc. | 2 | $106 |
| Amgen(2 entities) | 5 | $79 |
| Biotissue Holdings Inc. | 4 | $75 |
| Oyster Point Pharma, Inc. | 4 | $71 |
| Tarsus Pharmaceuticals, Inc. | 2 | $70 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Coopervision Inc. | 1 | $28 |
| Harrow Eye, LLC | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOTEMAX$1,500
- BESIVANCE$1,500
- VYZULTA$1,500
- PROLENSA$1,500
- CEQUA$348
- Tecnis IOL$347
- Clareon$290
- XEN GLAUCOMA TREATMENT SYSTEM$237
- OMNI(R) SURGICAL SYSTEM (US)$145
- AcrySof IQ VIVITY IOL$145
- RXSIGHT CONTACT LENS$132
- RXSIGHT INJECTOR CARTRIDGE$132
- RXSIGHT INJECTOR HANDPIECE$132
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$132
- LIGHT ADJUSTABLE LENS (LAL)$132
- AcrySof IQ PanOptix UV IOL$131
- TEARCARE SYSTEM$128
- Tobradex ST$126
- DURYSTA$125
- MIEBO$120
How this compares
$6,483 in reported general payments places this provider in the 95th percentile of 1,357 optometrist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 118 | $68,802 |
| VyzultaLatanoprostene Bunod | 42 | $22,400 |
| CombiganBrimonidine Tartrate/Timolol | 61 | $21,485 |
| XiidraLifitegrast | 26 | $18,605 |
| RhopressaNetarsudil Mesylate | 31 | $14,161 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 48 | $12,340 |
| Brimonidine Tartrate | 130 | $11,975 |
| CequaCyclosporine | 15 | $11,964 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $9,646 |
| Timolol Maleate | 214 | $7,231 |
| Latanoprost | 559 | $4,716 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 236 | $4,428 |
| Alphagan PBrimonidine Tartrate | 23 | $4,397 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $4,171 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 20 | $3,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $1,061 | $94,684202 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $154 | $41,00568 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $112 | $23,80751 claims |
| AlconSimbrinza | $658 | $12,34048 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $451 | $11,96415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 optometrist providers in New Jersey.
Other optometrist in Iselin
- Melanne RosettaIselin$66K
- Eric DevoreIselin$17K
- Muhammad ShahbakhtIselin$13K
- Natalie NguyenIselin$10K
- Frances TsaiIselin$6K
- Carly CrapanzanoIselin$6K
- Kerry GelbWoodbridge$264K
- Rodolfo RodriguezNorth Bergen$244K
- Steven SorkinFairfield$146K
- Paul VaccarellaRockaway$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.